Olema Gains 28 Hedge Fund Holders, Secures $60 and $48 Price Targets
Shares of Olema Pharmaceuticals attracted 28 new hedge fund holders during Q4 2025, boosting institutional interest. Citi maintained a Buy rating with a $60 price target and Stifel initiated coverage at $48, while COO/CFO Shane Kovacs departed and CEO Sean Bohen took on interim finance duties.
1. Hedge Fund Momentum Surges
Olema Pharmaceuticals added 28 hedge fund holders in Q4 2025, ranking among the top 15 stocks for institutional momentum. This increase reflects growing confidence in the company’s pipeline of next-generation targeted therapies for women’s cancers.
2. Bullish Analyst Ratings and Price Targets
Citi reaffirmed its Buy rating on Olema with a $60 price target, while Stifel launched coverage with a Buy rating and $48 target. Stifel’s model forecasts peak palazestrant sales of $3.1 billion by 2035 and notes the endocrine therapy market could exceed $20 billion globally.
3. Finance Leadership Transition
On January 30, COO and CFO Shane Kovacs resigned to pursue new opportunities and will remain as a consultant through August 1, 2026. CEO Sean Bohen has assumed principal finance responsibilities on an interim basis pending appointment of a successor.